matter news
Sangamo Therapeutics CEO Sandy Macrae on pioneering genetic cures
Last November, Sangamo Therapeutics made medical history by treating the first patient with an in vivo genome-editing therapeutic delivered intravenously to “edit” cells within the patient’s body. In a recent talk at MATTER, Sangamo CEO Sandy Macrae discussed how the company’s zinc finger technology for gene editing will fundamentally change how we care for patients and treat disease. Watch the…